CRISPR Therapeutics
CRSP
64 hedge funds and large institutions have $180M invested in CRISPR Therapeutics in 2017 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 3 closing their positions.
833% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 3
200% more funds holding in top 10
Funds holding in top 10: 2 → 6 (+4)
133% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 6
64% more funds holding
Funds holding: 39 → 64 (+25)
16% more capital invested
Capital invested by funds: $155M → $180M (+$24.5M)
0.68% more ownership
Funds ownership: 24.09% → 24.77% (+0.68%)
97% less call options, than puts
Call options by funds: $27K | Put options by funds: $983K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTP
Global Thematic Partners
New York
|
+$10.3M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.75M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
+$2.42M |
| 4 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
+$1.77M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$1.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$12.9M |
| 2 |
A
Abingworth
London,
United Kingdom
|
-$8.57M |
| 3 |
PC
Paulson & Co
New York
|
-$457K |
| 4 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$314K |
| 5 |
PCMM
Private Capital Management (Minnesota)
Eagan,
Minnesota
|
-$80K |
CRSP Hedge Fund Activity: Q3 2017 in Review
64 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q3 2017, worth a combined $180M — up 16% from $155M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new CRSP positions and 3 closed out — a net gain of 25 holders — while 14 added to existing stakes and 6 trimmed.
The largest buyer was Global Thematic Partners, opening a new position worth an estimated $10.3M. The largest seller was Morgan Stanley, cutting an estimated $12.9M.
- 64 institutional investors held CRISPR Therapeutics (CRSP) as of Q3 2017, up from 39 in Q2 2017.
- Funds reported $180M of CRISPR Therapeutics stock for Q3 2017, up 16% quarter-over-quarter.
- 28 funds opened new CRISPR Therapeutics positions in Q3 2017 and 3 closed out, a net change of +25 holders.
- The largest CRISPR Therapeutics buyer in Q3 2017 was Global Thematic Partners, an estimated $10.3M added.
- The largest CRISPR Therapeutics seller in Q3 2017 was Morgan Stanley, an estimated $12.9M sold.
Based on aggregated 13F filings for Q3 2017.